Locust Walk partnered with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd. Q2 saw a boom in IPOs, while many biopharma companies continue to seek capital in both public and private markets, including multiple crossover rounds — a key factor that has helped the industry ride through the COVID-19 market disclocations.
To further discuss the positive industry perception, we were proud to partner with Applied Molecular Transport, a clinical-stage biopharma company developing novel oral biologics to treat autoimmune, inflammatory, metabolic, and other diseases. In June of this year, they announced the closing of its IPO.
In addition, Forma Therapeutics, a clinical-stage biopharma company focused on rare hematologic diseases and cancers, also announced the closing of its IPO in June.
Geoff Meyerson, Moderator, CEO & Co-Founder, Locust Walk
Liz Bhatt, CBO, Applied Molecular Transport
Shawn Cross, CFO, Applied Molecular Transport
Seo Salimi, Partner, Life Sciences Capital Markets Group, Goodwin
Todd Shegog, CFO, Forma Therapeutics